← board
SER
distress 6/10 · elevated risk$2.20+1%today-63% from 52w high
Lead: advanced Parkinson's disease · est. market ~$6B (approx, global)
Revenue
pre-revenue
Liquidity
$25M
Runway
1.4 yrs
Shares 1y
+46%
Price & events
-25.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.5%
1D
+11.2%
1W
+14.7%
1M
+13.5%
3M
-23.3%
6M
-60.2%
1Y
-76.8%
2Y
-95.9%
5Y
-96.1%
All
Overview
- Market Cap
- $33.02M
- Volume
- 16.64K
- 52 Week Range
- $1.28 – $5.96
- Total Shares
- 15.00M
- Float Shares
- 8.41M
- Short %
- 2.48%
- % Held by Insiders
- 85.96%
- % Held by Institutions
- 9.84%
- RVOL
- 0.17x
- Beta
- 0.03
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- Q1 2026trial initiationsecondaryPhase 1SER-252 · Initiate enrollment in U.S. for Phase 1b trialSEC 8-K
- 2026-01-28fda agreementSER-252 · FDA cleared IND for SER-252 in advanced Parkinson's diseaseSEC 8-K
- Q4 2025trial initiationsecondaryPhase 1SER-252 · Begin dosing patients in Australia in Phase 1b trialSEC 8-K
- Q4 2025regulatory submissionFiled (NDA/BLA)SER-252 · Submit U.S. IND application for SER-252SEC 8-K
- 2025-11-25clinical holdSER-252 · FDA placed clinical hold on IND pending info on formulation excipientSEC 8-K
- 2025-08-25fda agreementSER-252 · FDA written feedback supports advancing SER-252 (POZ-apomorphine) in a registrational clinical study program in advanced Parkinson's under 505(b)(2) NDA pathwaySEC 8-K
- 2025-04-25partnershipCapital on Demand Sales Agreement for up to $13.27M of common stockSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+331% upside) · 2 analysts
- 2026-07-01BTIGBuy
- 2025-08-28HC Wainwright & Co.Buy
- 2025-07-14HC Wainwright & Co.Buy
- 2025-03-11Jones TradingBuy
Competitors — advanced Parkinson's disease
- none identified
Recent news
- 2026-07-23Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
- 2026-07-23Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Yahoo Finance UK
- 2026-07-22Serina Therapeutics Adds Industry Veteran to Board - TipRanks
- 2026-07-22Serina Therapeutics appoints Farrell Simon to Board, joins Audit and Compensation Committees - TradingView
- 2026-07-22Serina Therapeutics Appoints Farrell Simon to its Board of Directors - Yahoo Finance
- 2026-07-22Form 13D/A SERINA THERAPEUTICS For: 22 July By Investing.com - Investing.com Canada
- 2026-07-09Serina Therapeutics director Brannan buys $2,029 in stock By Investing.com - Investing.com Nigeria
- 2026-07-09Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson?s Disease - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.